HEPA - Hepion Pharmaceuticals, Inc. EV/EBITDA Multiple

Hepion Pharmaceuticals, Inc. (HEPA) - corporate logo

This EV/EBITDA price chart for Hepion Pharmaceuticals (HEPA) demonstrates a metric of , while management optimizes clinical trial expenses to attract strategic partners. Hepion Pharmaceuticals (HEPA) is actively developing its portfolio of anti-fibrosis and NASH treatments, confirming the therapeutic value of its developments. The business leverages the massive potential of the anti-inflammatory market, creating solutions for individuals with chronic liver pathologies.

HEPA (Hepion Pharmaceuticals, Inc.) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization history from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for Hepion Pharmaceuticals, Inc. (HEPA)

- market price and analyst price targets:
Summary company analysis:Hepion Pharma HEPA
Original product of hepionpharma.com

High debt loads for capital-intensive companies create a risk of insolvency during sharp revenue declines. The diversification of Hepion Pharmaceuticals (HEPA) developments across several therapeutic areas mitigates these threats, providing a fundamental margin of safety. By analyzing the Enterprise Value to EBITDA ratio, an investor assesses the total business value relative to operating profit, determining the asset's real attractiveness while accounting for all liabilities.